Charles A. Schiffer, MD

Clinical Applications for Asciminib in CML

John C. Molina, MD, EdM, reviews data from the 3-year update from the OPTIC study, and other experts offer their impressions.

Charles A. Schiffer, MD, an expert on chronic myeloid leukemia

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH

REMIX: Real-World Effectiveness of Ixazomib with Lenalidomide and Dexamethasone in MM

Experts in the field of chronic myeloid leukemia discuss the role of asciminib in the overall treatment landscape.

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH

Cross Q&A: Retrospective Study of Patients With MM

Faiz Answer, MD, FACP, reviews data from the REMIX study on the real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Jeffrey A. Zonder, MD, an expert on multiple myeloma

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH

ASCEMBL: Recent Data Updates for Asciminib in CML

Experts in the field of multiple myeloma discuss data from a retrospective study on patients with multiple myeloma.

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH

Potential Role of Olverembatinib in CML

Charles A. Schiffer, MD, reviews clinical trial data for asciminib in chronic myeloid leukemia and highlights financial toxicity concerns.

Moaath Mustafa Ali, MD, MPH, an expert on chronic myeloid leukemia

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH

Outcomes After Biochemical or Clinical Progression in Patients with MM

The expert panel discusses the potential role of olverembatinib in the chronic myeloid leukemia treatment landscape.

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH

Cross Q&A: Efficacy of CAR T-Cell Therapy in MM

Jeffrey A. Zonder, MD, reviews data on patient outcomes following biochemical or clinical progression in multiple myeloma.

Jack Khouri, MD, an expert on multiple myeloma

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH

Olverembatinib in Patients with Pretreated/Refractory CML

The expert panel discusses the efficacy and durability of response of ciltacabtagene autoleucel in patients with multiple myeloma.

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH

Treatment Considerations for Ponatinib in Patients With CML

Moaath Mustafa Ali, MD, MPH, reviews data on olverembatinib in patients with heavily pretreated/refractory chronic myeloid leukemia.

Jay Yang, MD, an expert on chronic myeloid leukemia, presenting clinical trial data

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH

CARTITUDE-4: Cilta-Cel in Lenalidomide-Refractory MM

Expert perspectives on treatment considerations for ponatinib in patients with chronic myeloid leukemia.

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH

Cross Q&A: Treatment Considerations for Ixa-Pom-Dex in Multiple Myeloma

Jack Khouri, MD, discusses phase 3 results from the CARTITUDE-4 study investigating ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.

Andrew Kin, MD, an expert on multiple myeloma

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH

Ponatinib Dose-Ranging Data in Chronic-Phase CML

Following a review of data from the ALLIANCE A061202 study, experts on multiple myeloma discuss treatment considerations for patients being treated with ixazomib, pomalidomide, and dexamethasone.

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH

Team Introductions: CML Experts From Karmanos Cancer Institute and Cleveland Clinic

Jay Yang, MD, reviews data from the OPTIC trial, a ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia.

The host of Cancer Network's Face-Off program shown with an introductory slide

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH

ALLIANCE A061202: Ixazomib Plus Pomalidomide and Dexamethasone in Multiple Myeloma

A panel of experts on chronic myeloid leukemia from Karmanos Cancer Institute and Cleveland Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent data in the disease space.

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH

Team Introductions: MM Experts From Karmanos Cancer Institute and Cleveland Clinic

Andrew Kin, MD, reviews data on the addition of ixazomib to pomalidomide and dexamethasone in patients with multiple myeloma who progressed on lenalidomide in the first line.

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH

POINT: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML

A panel of experts on multiple myeloma from Karmanos Cancer Institute and Cleveland Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent data in multiple myeloma.

First-Line Treatment for Patients With CML in Chronic Phase: Why Imatinib Is an Appropriate Choice

March 15th 2017

Which TKI Should Be Recommended as Initial Treatment for CML in Chronic Phase?

August 15th 2013

I am very comfortable in using imatinib as initial therapy in most patients who present in chronic phase, with the possible exception of patients with more advanced disease and higher Sokal scores.

Second-Generation TKIs in Chronic Myelogenous Leukemia

October 12th 2012

Resistance due to new mutations in the genes coding for the targeted proteins, as well as to changes in other signaling pathways, often develops, and newer drugs and perhaps combination approaches may be needed.

Commentary (Schiffer)-Thrombopoietin: Biology and Potential Clinical Applications

April 15th 2008

Chronic myelogeneous leukemia (CML) is a biologically unique neoplasm resulting from a mutation producing a single abnormal protein that induces unregulated proliferation of myelopoiesis. Imatinib mesylate (Gleevec) profoundly inhibits the chimeric bcr/abl tyrosine kinase, and has dramatically improved the outlook for patients with CML in chronic phase.